ClinicalTrials.gg

Program

Clonidine

Also written as “Ropivacaine + Clonidine + Betamethasone”, “Naltrexone and Clonidine Combination” and “Clonidine Gel 0.1%”.

Its studies are mostly in Low Back Pain · Diabetic Neuropathies · Attention Deficit Disorder with Hyperactivity · Hypertension, led by 3 companies.

Furthest: phase 4, since Aug 11, 20113 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Annette C. Toledano MD10 open or runningphase 2since Aug 11, 2011Aug 11, 2011none ahead
BioDelivery Sciences International10 open or runningphase 2since Feb 19, 2014Feb 19, 2014none ahead
Concordia Pharmaceuticals Inc., Barbados10 open or runningphase 4since Sep 13, 2011Sep 13, 2011none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 11, 2011First study: phase 2 study in Back PainNew to Annette C. Toledano MDAnnette C. Toledano MD · NCT01415895 · 78 enrolled · United States
  2. Sep 13, 2011Concordia Pharmaceuticals Inc., Barbados's first study: phase 4 study in Attention Deficit Disorder with HyperactivityNew to Concordia Pharmaceuticals Inc., BarbadosConcordia Pharmaceuticals Inc., Barbados · NCT01439126 · 135 enrolled
  3. Feb 19, 2014BioDelivery Sciences International's first study: phase 2 study in Diabetic NeuropathiesNew to BioDelivery Sciences InternationalBioDelivery Sciences International · NCT02068027 · 260 enrolled · United States

TargetBeta

“Adrenergic receptor alpha-2 agonist; Adrenergic receptor alpha-2 agonist”ChEMBL 37, by rule

Other programs on the same three targets

ProgramCompanyFurthest phaseStudies
brimonidineruleAbbViephase 454
DexmedetomidinerulePfizerphase 446
OxymetazolineruleAbbViephase 420
Phentolamineruleopus-genetics-incphase 418
Epinephrinerulenasus-pharmaphase 417
tizanidineruleTeva Pharmaceutical Industriesphase 411
lofexidineruleuswm-llc-dba-us-worldmedsphase 315

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT02068027Diabetic Neuropathies · United States2CompletedBioDelivery Sciences InternationalMar 2015260
NCT01439126Attention Deficit Disorder with Hyperactivity4CompletedConcordia Pharmaceuticals Inc., BarbadosOct 2012135
NCT01415895Back Pain · United States2CompletedAnnette C. Toledano MDFeb 201378

How it is read

Names in the registry

  • “Ropivacaine + Clonidine + Betamethasone”, 3 entries
  • “Naltrexone and Clonidine Combination”, 1 entry
  • “Clonidine Gel 0.1%”, 1 entry
  • “clonidine hydrochloride”, 1 entry
  • “Clonidine”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.